Study summary · research use only
BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review article (species not specified) discusses BAM15, a selective mitochondrial uncoupler, as a potential therapeutic agent across metabolic, neurodegenerative, cardiovascular, and cancer-related diseases. The authors describe BAM15's mechanism of disrupting coupling between electron transport and ATP synthesis, increasing mitochondrial respiration and energy expenditure, and summarize research showing BAM15 increased energy expenditure and reduced fat accumulation in obesity, improved glycemic control and reversed insulin resistance in diabetes, and showed potential in non-alcoholic fatty liver disease, sepsis, and cardiovascular disease by reducing oxidative stress, modulating inflammatory responses, and supporting cardioprotection. The authors describe BAM15 as having minimal adverse effects in described studies, while noting its high lipophilicity and need for alternative delivery methods as remaining challenges.
Abstract
Subcellular organelles dysfunction is implicated in various diseases, including metabolic diseases, neurodegenerative diseases, cancer, and cardiovascular diseases. BAM15, a selective mitochondrial uncoupler, has emerged as a promising therapeutic agent due to its ability to enhance mitochondrial respiration and metabolic flexibility. By disrupting the coupling between electron transport and ATP synthesis, BAM15 dissipates the proton gradient, leading to increased mitochondrial respiration and energy expenditure. This review provides a comprehensive overview of BAM15, including its mechanism of action and potential therapeutic applications in diverse disease contexts. BAM15 has shown promise in obesity by increasing energy expenditure and reducing fat accumulation. In diabetes, it improves glycemic control and reverses insulin resistance. Additionally, BAM15 has potential in non-alcoholic fatty liver disease, sepsis, and cardiovascular diseases by mitigating oxidative stress, modulating inflammatory responses, and promoting cardioprotection. The safety profile of BAM15 is encouraging, with minimal adverse effects and remarkable tolerability. However, challenges such as its high lipophilicity and the need for alternative delivery methods need to be addressed. Further research is necessary to fully understand the therapeutic potential of BAM15 and optimize its application in clinical settings.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.